The increase in awareness in regards with the benefits of using gene therapy as compared to conventional therapy for the treatment of various diseases and government support to promote gene therapy related research are the major driving factors that are projected to boost the market growth.
Gene-fixing treatments have now cured a number of patients with cancer and rare diseases. Genes are composed of DNA that contains necessary information for making proteins that are vital for the human body to function optimally. Some gene mutations result in these proteins not being made correctly and can lead to genetic disorders. Gene therapy works by repairing, repressing, or replacing dysfunctional genes that cause disease with the aim of reestablishing normal function. Gene therapy is an attractive area for drug development because with the right target and approach, it can address the root cause of a severe disease. For certain disorders where known genetic mutations lead to deficient or non-functional protein production, gene therapy can fix the underlying defect and provide a path to produce the functional protein.
Check out the “Gene Therapy” Research Report and Get the Sample PDF at: https://tinyurl.com/y77mcfae
Gene therapy—the idea of modifying a person’s DNA to treat disease—represents a major shift in medicine. Instead of just treating symptoms like the vast majority of drugs on the market, gene therapy aims to correct the underlying genetic cause of a disease. Doctors and scientists hope these treatments will be a one-shot cure.
Last year, we wrote that 2016 was gene therapy’s most promising year. But 2017 proved to be even bigger. Gene therapy had a hell of a 2017. After decades of promises but failed deliveries, last year saw the field hitting a series of astonishing home runs.
The concept of gene therapy is elegant: like computer bugs, faulty letters in the human genome can be edited and replaced with healthy ones.
But despite early enthusiasm, the field has suffered one setback after another. At the turn of the century, the death of an 18-year-old patient with inherited liver disease after an experimental gene therapy treatment put the entire field into a deep freeze.
But no more. Last year marked the birth of gene therapy 2.0, in which the experimental dream finally became a clinical reality. Here’s how the tech grew into its explosive potential—and a sneak peek at what’s on the horizon for 2018.
The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Due to the high success rate during the preclinical and clinical trial, gene therapy is gaining popularity. There are many techniques used for gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal.
Tumor suppressor and suicide gene therapy are expected to be a lucrative segment for the market players as they are among the fastest growing segment in the gene therapy market. The therapy involves the introduction of new genes into the tumor cells that help destroy the tumor cells without affecting the neighboring healthy cells.
How Does Gene Therapy Work?
Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.
A quality that is embedded straightforwardly into a cell more often than not does not work. Rather, a bearer called a vector is hereditarily built to convey the quality. Certain infections are frequently utilized as vectors since they can convey the new quality by contaminating the cell. The infections are adjusted so they can’t cause sickness when utilized as a part of individuals. A few kinds of infection, for example, retroviruses, incorporate their hereditary material (counting the new quality) into a chromosome in the human cell. Different infections, for example, adenoviruses, bring their DNA into the core of the phone, however the DNA isn’t incorporated into a chromosome.
The vector can be infused or given intravenously (by IV) specifically into a particular tissue in the body, where it is taken up by singular cells. On the other hand, an example of the patient’s cells can be evacuated and presented to the vector in a research facility setting. The cells containing the vector are then come back to the patient. On the off chance that the treatment is fruitful, the new quality conveyed by the vector will make a working protein.
Specialists must defeat numerous specialized difficulties previously quality treatment will be a reasonable way to deal with treating ailment. For instance, researchers must discover better approaches to convey qualities and target them to specific cells. They should likewise guarantee that new qualities are absolutely controlled by the body.
The key players operating in the global gene therapy market include Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, and NewLink Genetics Corp.
Other prominent players in the value chain include Amgen, Epeius Biotechnologies, Abeona Therapeutics, Sanofi, UniQure, Juno Therapeutics, Adaptimmune, Celgene, and Advantagene.
Do purchase Inquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2841
A new report published by Allied Market Research titled, “Asthma and COPD Drugs Market by Disease and Medication Class – Global Opportunity Analysis and Industry Forecasts, 2014-2022”, projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America accounted around for around half of the Global Asthma and COPD Drugs market share in 2015.
Increase in incidence and prevalence of asthma and COPD, growing geriatric population, technological advancement in the treatment of asthma and COPD diseases, growth in initiatives implemented by the government and non-government associations around the Global are the factors that majorly drive the growth of this market. However, stringent government regulations for the product approval, patent expiry of branded drugs, and side effects associated with drugs restrict the market growth.
Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-free-sample/311
In 2015, the asthma segment accounted for over 65% share of the overall Asthma and COPD Drugs market. Increase in introduction of generic drugs, and rising prevalence of asthma coupled with geriatric population and changes in lifestyle are the major factors that attribute to the rise in growth of this market.
Among the medication classes, the combination products segment held major share of the Global COPD and asthma drug market in 2015. This segment is expected to maintain its leading position in the overall market throughout the analysis period, primarily because of increase in focus on the effective asthma and COPD management and increase in the research and development of innovative treatment of the diseases.
North America led the market share in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the Asthma and COPD Drugs market in these regions attributes to the increase in the asthma and COPD patients, technological advancement in the treatment. However, Asia-Pacific is projected to be the fastest-growing region, registering a CAGR of 5.1% during the analysis period. This is mainly due to the increase in adoption rate for the technological advancement for treating asthma and COPD diseases. In addition, increase in research outsourcing from emerging markets, improvement of healthcare infrastructures, and increase in expenditures in the emerging markets (such as India and China) have boosted the market growth.
Do Enquiry before purchasing Report @ https://www.alliedmarketresearch.com/purchase-enquiry/311
The key players in the Asthma and COPD Drugs market are highly focused on expanding their business operations in the fast-growing emerging countries with new product launches as the preferred strategy. The key players profiled in this report include GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries(Israel), Vectura Group (U.K), and Pfizer Inc. (U.S).
Read similar market research reports on Pharmaceuticals at: https://www.alliedmarketresearch.com/life-sciences/Pharmaceuticals-market-report
Global Analgesics Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $26.4 billion by 2022, registering a CAGR of 7.7% during the period 2015-2022. The non-opioids segment would continue to be the highest revenue-generating segment throughout the forecast period. North America and Europe, are likely to continue their lead through 2022; they collectively accounted for over half of the overall market share in the global analgesics market in 2015.
Frequent pain and aches experienced by the ageing population, increasing incidences of cardiovascular disease (CVD), cancer, & arthritis, and rising investments in R&D by the public & private sectors, with key focus on the classes of compounds to formulate new therapeutics, are the major factors boosting the market growth. However, factors such as uncontrolled prescriptions of opioids and drug abuse, leading to approximately 28,000 deaths in the U.S. every year, and insufficient regulatory guidelines, especially against opioid analgesics, are likely to impede the market growth. Furthermore, the increase in popularity of personalized medicine is expected to provide numerous growth opportunities for the analgesics market in the near future.
Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-free-sample/1254
North America accounted for a major share of the overall analgesics market revenue in 2015, owing to a large number of pharmaceutical companies in this region. The analgesics market in developing economies, such as China and India, has numerous growth opportunities because of the availability of cheap raw materials and economical workforce. The global analgesics manufacturers are relocating their facilities into developing economies by agreements or acquisitions with local players. Moreover, increasing use of analgesics in countries such as Nigeria, China, and India supports the growth of analgesics in developing economies.
The key companies profiled in the report are Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi S.A.
Do Enquiry before purchasing Report @ https://www.alliedmarketresearch.com/purchase-enquiry/1254
Stress is the Driving Factor of the Male Infertility Market, Takes the Market to $301.5 Million, Globally, by 2020
Geographically, male infertility is segmented in to North America, Europe, Asia Pacific and RoW. The geographic market would be dominated by the North American region by 2020. This is due to the increased adoption of newer techniques such as DNA fragmentation in the routine analysis test for male infertility. The Asia Pacific and RoW region are expected to have the highest CAGR during the analysis period. This is due to the increase in male infertility awareness and rising awareness about the treatments that are available.
Male Infertility Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $301.5 million by 2020, registering a CAGR of 5% during the period 2014-2020.
Read more about this report: https://www.alliedmarketresearch.com/male-infertility-market
Infertility in male is characterized by various infertility related problems such as low sperm count, presence of low motile sperm or azoospermia. The various causes of male infertility include stress, consumption of alcohol or drugs, smoking, obesity, environmental toxins, etc. These factors also act as driving factors of the male infertility market. When an individual is diagnosed with infertility, the person undergoes immense stress, embarrassment and guilt, which would further intensify the infertility problem. This is a major limitation of this market. The opportunity for the growth of this market
is the increase in awareness levels among men and rising trend in medical tourism.
The male infertility market is segmented based on techniques, namely DNA fragmentation, oxidative stress analysis, sperm agglutination test, sperm penetration test, microscopic examination, computer assisted semen analysis and others. The DNA
fragmentation would be the highest revenue generating market by 2020 and is also expected to have the highest CAGR during the analysis period, when compared to the other segments in the techniques market. This is due to the accuracy level the test provides in identifying the level of infertility by measuring the level of DNA damage.
The key companies profiled in the report are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, Andrology Solutions.
Male Infertility Market Segments covered in the report:
- By Techniques
DNA Fragmentation Technique
Oxidative Stress Analysis
Sperm Penetration Assay
Computer Assisted Semen Analysis
- By Geography
Global Smart Inhalers Market states that the market was $5.8 million in 2015 and is expected to reach $191 million by 2022, growing at a CAGR of 63.3% from 2016 to 2022, according to new research published by Allied Market Research. The inhalers segment captured majority share in 2015, whereas nebulizers segment is projected to grow at fastest CAGR of 64.1% during the forecast period. North America, which accounted for around two-fifths share in 2015, is expected to maintain its lead throughout.
Smart inhalers promote adherence to inhalers and also send timely reminders to patients to take their inhaler dose at the required time due to which it has emerged as a novel approach in asthma and COPD management. The major factors that drives the smart inhalers market include worldwide growth in population susceptible to indoor air pollutants, inclination of patients towards digitalized medical devices for monitoring daily medication doses, and rise in prevalence of asthma and COPD. In addition, improved smart inhalers adherence rate and increase in collaboration between pharmaceutical companies and smart inhaler manufacturers promotes technological advancements which would ultimately support the market growth. These smart inhalers directly transfer medication data to the mobile application as well as to the cloud server connected through the internet. Thus, assuring doctor on exact medicine intake and frequency of the same. However, data privacy and limited availability of smart inhalers across regions acts as a major limitation in the market growth.
Read more details of the report at: https://www.alliedmarketresearch.com/smart-inhalers-market
Smart inhaler products comprise sensors that can be easily attached on the traditional inhalers and nebulizers. The inhalers segment accounted for major share of the overall market, as inhalers are preferred as first option of treatment, portability, and cost effectiveness leading to volume sales. However, nebulizers are expected to grow at the fastest rate due to technological advancements that result in their portability and ease of use.
North America accounted for the majority of the revenue in 2015 owing to the increased adoption of smart inhalers and increased awareness about asthma and COPD treatment. Asia-Pacific is projected to be the fastest growing region throughout the analysis period with major revenue contribution from China. Improvement in healthcare infrastructure and increase in healthcare expenditure in the emerging markets (such as India and China) is projected to fulfill the unmet medical needs thus, fueling the smart inhalers market growth in the Asia-Pacific region.
Key findings of the smart inhalers market study:
- In the year 2015, inhalers led the global smart inhalers market revenue, and is projected to grow at a CAGR of 63.2%.
- Smart inhalers market for asthma is expected to grow at a CAGR of 62.0%, in terms of revenue, whereas for COPD, is expected to grow at a CAGR of 64.5%.
- COPD indication segment is expected to grow at a CAGR of 64.5% due to increase in COPD incidence rate, rise in adherence rate.
- The majority of smart inhalers are used by R&D centers and this trend is expected to be continued during the forecast period.
- Europe and Asia-Pacific together accounted for around half of the market share in 2015.
- China is the major shareholder, accounting for about one-third share of the Asia-Pacific smart inhalers market, in terms of value.
- U.S. smart inhalers market is expected to grow at a CAGR of 59.5%.
- German smart inhalers market is expected to grow at a CAGR of 68.2% during analysis period.
Recent developments such as acquisition of Inspiro Medical by Opko Health, collaboration between Novartis and Qualcomm, and acquisition of Gecko Health by Teva pharmaceuticals for manufacturing smart inhalers further signify the increase in competition in the smart inhalers industry. These developments are majorly focused on manufacturing smart inhalers as well as launching new devices with inbuilt smart inhalers instead of using an add on sensor to the device; thereby positively increasing the market revenue as well as competition among the manufacturers.
Request free sample copy of this report at: https://www.alliedmarketresearch.com/request-free-sample/1715
Major players profiled in this report include Vectura Group plc, Adherium Limited, Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations), AstraZeneca plc, Propeller Health, Cohero Health, LLC, Boehringer Ingelheim GmbH, OPKO Health, Inc. (Inspiro Medical Ltd.), GlaxoSmithKline plc, and Novartis AG.
Global Specialty Enzymes Market is Expected to Reach $947.5 Million, by 2020 – Allied Market Research
According to a new report by Allied Market Research titled, “World Specialty Enzymes for Pharmaceuticals, Biotechnology R&D and Diagnostics – Market Opportunity and Forecast, 2014-2020″, the global specialty enzymes market is expected to register a CAGR of 9.4% during 2015-2020. The pharmaceuticals application segment accounted for about half of the overall market share in 2014. The Asia Pacific market would exhibit the highest CAGR of 11.7% during the forecast period (2015-2020).
Specialty enzymes are proteins that act as biocatalysts to accelerate chemical reaction and produce the desired results. Owing to low consumption and high degree of specificity, specialty enzymes are witnessing spurring demand in medical applications such as pharmaceutical, biotechnology research and diagnostics. The growing popularity of specialty enzymes in therapies for chronic diseases such as cancer, cardiovascular diseases, pain and inflammatory disorders among others is the vital force fuelling the market growth. In addition, growing awareness about enzyme-based therapeutics in the Asia Pacific and LAMEA region would further boost the market growth. However, safety concerns due to high vulnerability of enzymes towards contamination, would limit the overall market growth.
A new report published by Allied Market Research titled, “World Excipients Market—Opportunities and Forecasts, 2014–2020,” projects that the world excipients market would reach $6.4 billion by 2020 at a CAGR of 7.6% during 2015 and 2020. Organic chemicals would continue to be the highest revenue-generating segment during the forecast period. North America and Europe will continue to be the lead revenue generating economies through 2020. These regions collectively accounted for about three-fourth of share in the global excipients market in 2015.
Factors that drive the global excipients market are rising demand for pharmaceutical drugs, increasing popularity of functional excipients, drug pipeline, development of novel excipients, and increasing generic drugs market caused by expiration of various bestseller drugs patents. Factors that are likely to impede the market growth include, supply chain issues, high market fragmentation, and implementation of stringent regulations.